CORRESP Filing
NextCure, Inc.
Date: Dec. 9, 2025 · CIK: 0001661059 · Accession: 0001104659-25-119663
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291809
Letter
Re:
December 9, 2025
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Danny Crawford
NextCure, Inc. Registration Statement on Form S-3 File No. 333-291809
Acceleration Request
Requested Date: December 11, 2025
Requested Time: 4:00 P.M., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, NextCure, Inc. (the " Company ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (the " Registration Statement "), be accelerated so that the Registration Statement will become effective at 4:00 P.M., Eastern Time, on December 11, 2025, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
Please contact Nick DeAngelis of Sidley Austin LLP at (214) 969-3563 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.
Very truly yours,
/s/ Michael Richman
Show Raw Text
CORRESP 1 filename1.htm December 9, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Danny Crawford Re: NextCure, Inc. Registration Statement on Form S-3 File No. 333-291809 Acceleration Request Requested Date: December 11, 2025 Requested Time: 4:00 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, NextCure, Inc. (the " Company ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (the " Registration Statement "), be accelerated so that the Registration Statement will become effective at 4:00 P.M., Eastern Time, on December 11, 2025, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission. Please contact Nick DeAngelis of Sidley Austin LLP at (214) 969-3563 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement. Very truly yours, /s/ Michael Richman Michael Richman Chief Executive Officer NextCure, Inc. cc: Michael Richman, NextCure, Inc. Asher Rubin, Sidley Austin LLP Istvan A. Hajdu, Sidley Austin LLP Nick DeAngelis, Sidley Austin LLP